Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 with Topotecan or Temozolomide in Relapsed SCLC
NCT03554473Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in small cell lung cancer (SCLC), extrapulmonary small cell carcinoma (EPSCC), sponsored by National Cancer Institute. Started Sep 2018; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
small cell lung cancer (SCLC)extrapulmonary small cell carcinoma (EPSCC)
Beyond the preview
Go deeper on NCT03554473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554473.